The HOPE4MCI study: A randomized double-blind assessment of AGB101 for the treatment of MCI due to AD.
Richard MohsArnold BakkerSharon Rosenzweig-LipsonMichael RosenblumRussell L BartonMarilyn S AlbertSharon CohenScott ZegerMichela GallagherPublished in: Alzheimer's & dementia (New York, N. Y.) (2024)
The possibility that ApoE-4 carriers and noncarriers will respond differently to therapeutic intervention is consistent with recently reported findings from biologics and the present results show further testing of AGB101 in patients with MCI due to AD who are noncarriers of the ApoeE-4 allele is warranted. Conclusions from the HOPE4MCI study are limited primarily due to the small sample size and results can only be regarded as a guide to future research.